The purpose of this study is to assess the safety and tolerability of the investigational eye drop solution, PAN-90806. The biological response to the eye drops will also be assessed to see if the drug helps slow the progression of neovascular age-related macular degeneration. Participants (age 50 years and older) enrolled in the study will be randomized into one of three study arms (1 mg/ml BID, 2 mg/ml BID, 4 mg/ml QD).
Inclusion Criteria
-
Active, and previously untreated, subfoveal CNV lesions secondary to neovascular macular degeneration
-
Best-corrected visual acuity between 20/63 to 20/160 in the study eye
- Patient, or patient’s family member, must be willing and able to instill topical ocular drops in the study eye up to two times per day
Exclusion Criteria
- Additional eye disease in the study eye that would compromise best-corrected visual acuity
- Best-corrected visual acuity in the fellow eye of worse than 20/320
- Any prior ocular or systemic treatment or surgery for neovascular macular degneration in the study eye, with the exception of dietary supplements or vitamins
Study Requirements
After participants pass a screening visit, they will be asked to instill investigational eye drops for 8 weeks and come in for a total of 7 visits.
A total of 4 fluorescein angiograms and 4 blood collections will be required for the study
